Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Researchers develop new score to predict the risk of liver cancer

Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a score that predicts the risk of liver cancer.

17 Feb 2026

University of Missouri launches first on-campus radiopharmaceutical clinical trial

In a major leap for cancer care at the University of Missouri, the School of Medicine and MU Health Care have launched their first clinical trial using a leading-edge therapy manufactured on campus at the university's research reactor.

10 Feb 2026

Prognostic nutritional index proposed as prognostic marker in hepatocellular carcinoma

The prognostic nutritional index (PNI), calculated from serum albumin and lymphocyte count, reflects a patient's immune-nutritional status and has been proposed as a prognostic marker in hepatocellular carcinoma (HCC).

27 Jan 2026

Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with high hepatitis B virus prevalence.

24 Jan 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

Expert guidance on fecal microbiota transplantation in liver disease

The gut microbiota plays a crucial role in maintaining host health and liver function. Fecal microbiota transplantation (FMT), an emerging therapeutic modality, has demonstrated promising potential in the treatment of chronic liver diseases.

22 Jan 2026

Myosteatosis: An emerging predictor of outcomes in chronic liver disease

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of poor clinical outcomes across a spectrum of liver diseases.

22 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

A dual-action approach to preventing hepatocellular carcinoma

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of recurrence after surgery. Even after complete tumor removal, microscopic residual disease and early dissemination frequently lead to relapse within the first two years.

21 Jan 2026

Blocking liver enzyme Caspase-2 may increase long-term cancer risk

Scientists have discovered that blocking a key cellular enzyme thought to protect against fatty liver disease may instead increase the risk of chronic liver damage and cancer as we age.

13 Jan 2026

Using contrast-enhanced ultrasound to distinguish hepatic PEComa from HCC without high-risk factors

Announcing a new article publication for BIO Integration journal. Hepatic perivascular epithelioid cell tumor (PEComa) is a rare tumor with malignant potential that is frequently misdiagnosed as hepatocellular carcinoma (HCC), despite requiring distinct treatment approaches.

6 Jan 2026

Remodeling the tumor microenvironment to unlock CAR-T cell potential

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

22 Dec 2025

US cancer registries, constrained by Trump policies, to recognize only ‘male’ or ‘female’ patients

The top authorities of U.S. cancer statistics will soon have to classify the sex of patients strictly as male, female, or unknown, a change scientists and advocates say will harm the health of transgender people, one of the nation's most marginalized populations.

21 Nov 2025

Neoantigens-loaded DC vaccines show strong potential to overcome tumor resistance

Despite the success of immune checkpoint inhibitors in revolutionizing oncology, their benefits remain limited to a small fraction of patients.

19 Nov 2025

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

4 Nov 2025

Liver cirrhosis found to be more common in low-income households

Liver cirrhosis is significantly more common in low-income households than in high-income households. This is the result of a national study which, according to the researchers, calls for more preventive action in the most vulnerable groups.

28 Oct 2025

E2F2 protein identified as potential therapeutic target to prevent metabolic fatty liver disease progression

An international collaborative study has identified the E2F2 protein as a potential new therapeutic target to prevent metabolic fatty liver disease from progressing towards more serious conditions, such as cirrhosis or liver cancer.

22 Oct 2025

Groundbreaking 3D dynamic cell co-culture models simulate MASLD progression

In a recent work published in BME Frontiers, a collaborative study by researchers from Griffith University, Queensland University of Technology, University of Queensland, and Nanjing Stomatological Hospital has introduced groundbreaking three-dimensional (3D) dynamic cell co-culture models to simulate metabolic dysfunction-associated steatotic liver disease (MASLD) progression stages.